Biogen, Teva benefit as payers ease up on multiple sclerosis meddling: analyst

Teva's 40mg version of Copaxone is still holding up under generic pressure, Bernstein's Ronny Gal says. (Teva)

The multiple sclerosis field has been a hotbed for payers pressing drugmakers to trade formulary spots for discounts. But that’s changed a bit in 2018—and that means some MS-dependent companies can breathe a big sigh of relief.

This year, MS formularies are “less restrictive,” Bernstein analyst Ronny Gal pointed out in a recent note to clients, with just 24% of drugs blocked versus last year’s 42%. And if you compare the 2018 figure to 2016’s peak of 48% of drugs blocked, this year represents an even bigger shift.

The way Gal sees it, there’s now a “recognition by payers that the category is challenging to manage,” and they’ve responded with a “willingness to cover multiple drugs with the same mechanism of action,” he wrote.


Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

The result? More drugs now bear a “preferred” distinction among payers—77% versus 72% last year—and there is “no material advantage among them.” Companies with more than one MS drug have won formulary spots for a second drug, a “portfolio effect” that’s helped players such as Biogen and Novartis.

RELATED: Payers keep squeezing MS drugmakers—and they may just take their tactics elsewhere

Meanwhile, formulary management has yielded some surprises over at Teva, whose 20mg dose of blockbuster Copaxone has gotten the cold shoulder from payers in favor of generic Glatopa from Novartis’ Sandoz. But rather than switching to the generic, 20mg patients are instead switching drugs altogether, Gal noted.

RELATED: Teva's Copaxone holds its own in wake of Mylan's generic price cut

And on the 40mg Copaxone side, where Teva’s branded therapy and Mylan’s copy have similar coverage, Teva has kept its market share intact. “This seems to reflect some sort of a half-hearted attempt by the PBMs to push for a generic,” Gal said in a video, adding that “a physician preference for the brand given the complexity of the reference drug” and Teva’s patient assistance services are likely also playing a role.

Suggested Articles

Roche's Perjeta is looking to build its case as an add-on treatment to standard-of-care Herceptin plus chemo in HER2-positive breast cancer patients.

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.